China NT Pharma Group Company Limited (1011.HK)

HKD 0.27

(1.89%)

Net Debt Summary of China NT Pharma Group Company Limited

China NT Pharma Group Company Limited's latest annual net debt in 2023 was 343.42 Million CNY , down -58.15% from previous year.
China NT Pharma Group Company Limited's latest quarterly net debt in 2024 Q2 was 350.34 Million CNY , down 0.0% from previous quarter.
China NT Pharma Group Company Limited reported annual net debt of 820.52 Million CNY in 2022, down -0.26% from previous year.
China NT Pharma Group Company Limited reported annual net debt of 822.66 Million CNY in 2021, down -2.5% from previous year.
China NT Pharma Group Company Limited reported quarterly net debt of 840.65 Million CNY for 2023 Q2, down 0.0% from previous quarter.
China NT Pharma Group Company Limited reported quarterly net debt of 343.42 Million CNY for 2023 FY, down -58.15% from previous quarter.

Annual Net Debt Chart of China NT Pharma Group Company Limited (2023 - 2010)

Historical Annual Net Debt of China NT Pharma Group Company Limited (2023 - 2010)

Year	Net Debt	Net Debt Growth
2023	343.42 Million CNY	-58.15%
2022	820.52 Million CNY	-0.26%
2021	822.66 Million CNY	-2.5%
2020	843.76 Million CNY	-15.57%
2019	999.4 Million CNY	8.31%
2018	922.75 Million CNY	81.22%
2017	509.18 Million CNY	-36.58%
2016	802.82 Million CNY	1301.38%
2015	-66.82 Million CNY	-121.0%
2014	318.18 Million CNY	-19.61%
2013	395.79 Million CNY	31.87%
2012	300.14 Million CNY	96.82%
2011	152.49 Million CNY	-77.75%
2010	685.27 Million CNY	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	350.34 Million CNY	0.0%
2023 Q2	840.65 Million CNY	0.0%
2023 FY	343.42 Million CNY	-58.15%
2023 Q4	343.42 Million CNY	0.0%
2022 Q2	809.31 Million CNY	0.0%
2022 FY	820.52 Million CNY	-0.26%
2022 Q4	820.52 Million CNY	0.0%
2021 Q2	724.94 Million CNY	0.0%
2021 Q4	822.66 Million CNY	0.0%
2021 FY	822.66 Million CNY	-2.5%
2020 FY	843.76 Million CNY	-15.57%
2020 Q2	956.3 Million CNY	0.0%
2020 Q4	843.76 Million CNY	0.0%
2019 Q2	921.47 Million CNY	0.0%
2019 FY	999.4 Million CNY	8.31%
2019 Q4	999.4 Million CNY	0.0%
2018 Q2	414.45 Million CNY	0.0%
2018 FY	922.75 Million CNY	81.22%
2018 Q4	922.75 Million CNY	0.0%
2017 FY	509.18 Million CNY	-36.58%
2017 Q2	363.4 Million CNY	0.0%
2017 Q4	509.18 Million CNY	0.0%
2016 FY	802.82 Million CNY	1301.38%
2016 Q4	802.82 Million CNY	0.0%
2016 Q2	113.88 Million CNY	0.0%
2015 Q4	-66.82 Million CNY	0.0%
2015 FY	-66.82 Million CNY	-121.0%
2015 Q2	281.73 Million CNY	0.0%
2014 Q4	318.18 Million CNY	0.0%
2014 Q2	419.63 Million CNY	0.0%
2014 FY	318.18 Million CNY	-19.61%
2013 Q4	395.79 Million CNY	0.0%
2013 FY	395.79 Million CNY	31.87%
2013 Q2	574.59 Million CNY	0.0%
2012 Q2	213.77 Million CNY	0.0%
2012 Q4	300.14 Million CNY	0.0%
2012 FY	300.14 Million CNY	96.82%
2011 Q4	152.49 Million CNY	0.0%
2011 Q2	-9.57 Million CNY	0.0%
2011 FY	152.49 Million CNY	-77.75%
2010 Q4	685.27 Million CNY	0.0%
2010 FY	685.27 Million CNY	0.0%

Peer Net Debt Comparison of China NT Pharma Group Company Limited

Name	Net Debt	Net Debt Difference
Pak Fah Yeow International Limited	-258.7 Million HKD	232.748%
Grand Pharmaceutical Group Limited	2.03 Billion HKD	83.098%
Extrawell Pharmaceutical Holdings Limited	5.94 Million HKD	-5677.624%
Wai Yuen Tong Medicine Holdings Limited	301.53 Million HKD	-13.891%
Qianhai Health Holdings Limited	-19.03 Million HKD	1903.876%
Lee's Pharmaceutical Holdings Limited	30.94 Million HKD	-1009.674%
Essex Bio-Technology Limited	-219.22 Million HKD	256.65%
Tongfang Kontafarma Holdings Limited	256.16 Million HKD	-34.063%
PuraPharm Corporation Limited	377.54 Million HKD	9.039%
SSY Group Limited	1.71 Billion HKD	79.958%
JBM (Healthcare) Limited	-7.39 Million HKD	4741.465%
Jacobson Pharma Corporation Limited	337.44 Million HKD	-1.772%
China Resources Pharmaceutical Group Limited	50.97 Billion HKD	99.326%